Mr. Speaker, as we have said all along, the shortage results from a decision by the provinces and territories to sole source drug contracts. Our role is to ensure that the drugs are safe before they enter the market. We are working around the clock to address this issue by identifying new suppliers for the provinces and territories, fast-tracking approvals and providing access to the national emergency stockpile system.
Going forward, we are encouraging the provinces and the territories to ensure that the decision of one drug maker will not seriously disrupt our—